Abstract: A multi-modal visualization system (MMVS) is provided, which may be used to analyze and visualize bioimaging data, objects, and pointers, such as neuroimaging data, surgical tools, and pointing rods. MMVS can integrate multiple bioimaging modalities to visualize a plurality of bioimaging datasets simultaneously, such as anatomical bioimaging data and functional bioimaging data.
Abstract: The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences.
Type:
Application
Filed:
September 1, 2023
Publication date:
March 7, 2024
Applicant:
THE GENERAL HOSPITAL CORPORATION
Inventors:
Anthony John IAFRATE, Long Phi LE, Zongli ZHENG
Abstract: The invention provides methods and compositions for use in treating cancer, which advantageously may be achieved by targeting of the tumor microenvironment.
Abstract: Microfluidic devices for use with reagents bound to microspheres for determination of the concentration of an analyte in a liquid sample are provided. The devices include two sequential mixing channels that promote rapid binding of microsphere-bound reagents with reagents in solution and a means for detecting labeled microsphere-bound reaction products. Also provided are methods for using the devices with microsphere-bound reagents to determine the concentration of an analyte in a liquid sample and to measure the binding affinity of antibody for an antigen.
Type:
Grant
Filed:
August 16, 2019
Date of Patent:
March 5, 2024
Assignees:
Northeastern University, The General Hospital Corporation
Abstract: The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
March 5, 2024
Assignee:
The General Hospital Corporation
Inventors:
Mustafa Korkut Uygun, Bote G. Bruinsma, Maria-Louisa Izamis
Abstract: One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.
Abstract: Methods for reactivating genes on the inactive X chromosome that include administering one or both of a DNA methyltransferase (DNMT) Inhibitor and/or a topoisomerase inhibitor, e.g., etoposide and/or 5?-azacytidine (aza), optionally in combination with an inhibitor of XIST RNA and/or an Xist-interacting protein, e.g., a chromatin-modifying protein, e.g., a small molecule or an inhibitory nucleic acid (such as a small inhibitory RNA (siRNAs) or antisense oligonucleotide (ASO)) that targets XIST RNA and/or a gene encoding an Xist-interacting protein, e.g., a chromatin-modifying protein.
Type:
Grant
Filed:
March 26, 2021
Date of Patent:
February 27, 2024
Assignee:
The General Hospital Corporation
Inventors:
Jeannie T. Lee, Anand Minajigi, Lieselot Carrette
Abstract: The present invention provides methods and compositions based on a non-naturally occurring nucleic acid construct encoding a fusion protein for quantitating levels of secretion in a single cell which may comprise a protein sequence which may comprise a cytoplasmic domain, a transmembrane domain and a vesicular domain, wherein the vesicular domain may comprise a protein tag sequence, wherein upon expression of the fusion protein by a cell, the fusion protein localizes to the membrane of a secretory vesicle such that the protein tag localizes to the lumen of the secretory vesicle, and wherein the protein tag binds to a cell-impermeable marker; whereby upon secretion of the contents of the secretory vesicle, the protein tag is exposed to the cell-impermeable marker, the fusion protein is recycled back into the cell, and the single cell becomes labeled with the marker relative to the amount of secretion.
Type:
Application
Filed:
August 9, 2023
Publication date:
February 22, 2024
Applicants:
THE GENERAL HOSPITAL CORPORATION, THE BROAD INSTITUTE, INC.
Inventors:
Sean Burns, Jason Wright, Thomas Sundberg
Abstract: A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described.
Type:
Grant
Filed:
May 4, 2021
Date of Patent:
February 20, 2024
Assignees:
THE GENERAL HOSPITAL CORPORATION, THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.
Type:
Application
Filed:
September 15, 2023
Publication date:
February 15, 2024
Applicants:
The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
Inventors:
Margaret SHIPP, Gad GETZ, Bjoern CHAPUY, Kirsty WIENAND, Donald STEWART, Andrew DUNFORD, Mark MURAKAMI, Lee LAWTON
Abstract: The disclosure features methods of identifying specific drug candidates for disease treatment, the methods including: for pairs of associated expressed proteins in a protein-protein interaction network for a plurality of biological samples, comparing relative concentration values of the associated proteins in each of the biological samples to identify outliers among a distribution of the relative concentration values, identifying a set of proteins involved in dysregulated protein-protein interactions in the network based on the outliers, and predicting an efficacy of one or more drug candidates from among a set of drug candidates for treating a disease based on the identified set of proteins and information about one or more of proteins, protein complexes, biological pathways, and functional modules targeted by the set of drug candidates.
Abstract: Provided herein are methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.
Type:
Grant
Filed:
April 17, 2019
Date of Patent:
February 13, 2024
Assignee:
The General Hospital Corporation
Inventors:
J. Keith Joung, Vikram Pattanayak, Karl Petri
Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
Type:
Grant
Filed:
October 8, 2020
Date of Patent:
February 13, 2024
Assignee:
The General Hospital Corporation
Inventors:
Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.
Type:
Application
Filed:
October 16, 2023
Publication date:
February 8, 2024
Applicant:
The General Hospital Corporation
Inventors:
Lilit Garibyan, Richard Rox Anderson, William A. Farinelli, Emilia Javorsky
Abstract: The present disclosure relates to compositions and methods for detecting nucleic acid sequences (e.g., coding and non-coding RNAs; nuclear/genomic DNA; mtDNA; pathogen nucleic acids, etc.) in a tissue sample, specifically providing improved matrices and matrix-employing methods for performance of nucleic acid capture and amplification in a tissue sample in situ and/or in a manner that retains spatial location information for captured nucleic acids (including nucleic acid-associated macromolecules).
Type:
Application
Filed:
February 11, 2022
Publication date:
February 8, 2024
Applicants:
THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BROAD INSTITUTE, INC.
Inventors:
Evan Macosko, Nicolas Lapique, Michael Kim
Abstract: The invention described herein relates to methods and compositions for treating cancer in a patient, or a tumor cell, by administering an effective amount of an antibody-anti-fugetactic agent complex.
Abstract: Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array (TALE) or zinc finger array, and a catalytic domain comprising a sequence that catalyzes histone demethylation, and methods of use thereof.
Type:
Grant
Filed:
April 5, 2019
Date of Patent:
February 6, 2024
Assignee:
The General Hospital Corporation
Inventors:
Jae Keith Joung, Eric M. Mendenhall, Bradley E. Bernstein, Deepak Reyon
Abstract: Exemplary method and apparatus for diagnosing or characterizing an inflammation within an anatomical structure can be provided. For example, using at least one source arrangement, it is possible to provide at least one first electro-magnetic radiation to the anatomical structure at at least one first wavelength in vivo. With at least one detector arrangement, it is possible to detect at least one second electro-magnetic radiation at at least one second wavelength provided from the anatomical structure. The second radiation can be associated with the first radiation, and the first wavelength can be shorter than the second wavelength. The second radiation can be provided from the anatomical structure due to at least one change in the anatomical structure caused by the inflammation without providing an artificial fluorescence substance.
Type:
Grant
Filed:
January 28, 2021
Date of Patent:
February 6, 2024
Assignee:
The General Hospital Corporation
Inventors:
Hao Wang, Joseph A. Gardecki, Guillermo J. Tearney
Abstract: Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. The bioreactor comprises: an organ chamber: an ingres line connecting the organ chamber and a reservoir system and comprising an arterial line, a venous line and a tracheal line; an egress line connecting the chamber and the reservoir system, pumps in ingress and egress lines; a controller to control fluid exchange; a chamber pressure sensor connected to the organ chamber.